<ul>
<li><strong>拟议的融资交易将提供高达 1200 万美元的资金，以支持 Celularity 在延续生命和人类表现保护方面的战略优先事项。</strong></li>
</ul>
<p>新泽西州弗洛汉公园，2025 年 12 月 18 日（全球新闻通讯）——Celularity Inc.（纳斯达克：CELU）（“Celularity”），一家应对与年龄相关和退行性疾病的再生和细胞医学公司，今天宣布已与 DoubleLine Capital LP 的联合创始人及前总裁 Philip A. Barach 签署了两份具有约束力的条款清单，涉及一项高级担保定期贷款和一项担保可转换票据融资。这些拟议的融资交易取决于各方签署正式交易协议，各方预计将很快完成此项工作。</p>
<p>根据具有约束力的条款清单，Celularity 预计将获得 1000 万美元的初始收益，额外资金最多可达 200 万美元，具体取决于某些条件和投资者的选择，这将在最终协议中列明。</p>
<p>“完成这项融资后，预计将为我们进一步发展使命提供灵活性，聚焦于推进我们的核心胎盘衍生技术，并合理调整我们的组织结构和资源，以支持我们在延续生命和人类表现保护方面的战略优先事项，” Celularity 的董事长兼首席执行官 Robert J. Hariri 博士表示。“我们感谢 Phil Barach 在我们发展重要时刻与 Celularity 合作的承诺。Phil 的投资反映了对我们平台科学基础的深刻理解和我们所追求的长期愿景。”</p>
<p>根据具有约束力的条款清单，高级担保定期贷款的名义本金为 700 万美元，并以 Celularity 几乎所有资产的第一优先权利作为担保，受某些惯例排除和优先协议的限制。担保可转换票据提供高达 500 万美元的总承诺，可以分多个批次发行，并可按每股 1.66 美元的转换价格转换为 Celularity 的 A 类普通股，前提是符合适用的纳斯达克最低价格规则和联邦证券法要求。与拟议交易相关，Celularity 已同意发行购买其 A 类普通股的认股权证，数量相当于按转换后的本金金额的 33%，作为对投资者的额外对价。认股权证将在发行后六个月生效，行使价格为每股 2.00 美元，并受惯例条款和条件的限制。交易将作为对合格投资者的私募进行。</p>
<p>Philip A. Barach 评论道：“Hariri 博士建立了一家拥有开创性科学和大胆愿景的公司，我认为，通过更好地调整其战略、运营和资本结构，以符合其将有意义的科学转化为现实影响的使命，未来可以更充分地实现。我的投资决定和与公司的互动反映了对提供财务支持和建设性视角的长期承诺，因为 Celularity 在必要的变革中努力并为更有纪律和专注的未来做好准备。”</p>
<p>上述证券将在免于 1933 年证券法（经修订）（“法案”）注册要求的私募中出售，且未在法案或适用的州证券法下注册。因此，除非根据有效的注册声明或适用的注册豁免，否则这些证券不得在美国提供或出售，并且不得在任何州或司法管辖区进行此类提供、招揽或销售，除非在该州或司法管辖区的证券法下进行注册或资格审查。根据与投资者签订的注册权利协议，公司已同意向证券交易委员会（“SEC”）提交一份或多份注册声明，涵盖在私募中出售的可转换票据和认股权证所对应的 A 类普通股的转售。</p>
<p>本新闻稿不构成出售或招揽购买本文所述证券的要约，也不构成在任何州或司法管辖区进行这些证券的销售，除非在该州或司法管辖区的证券法下进行注册或资格审查。</p>
<p><strong>关于 Celularity</strong></p>
<p>Celularity Inc.（纳斯达克：CELU）是一家再生和与衰老相关的细胞医学公司，开发、制造和商业化先进的生物材料产品以及源自产后胎盘的异体和自体细胞疗法。Celularity 相信，通过利用胎盘独特的生物学和现成的可用性，可以开发出解决全球有效、可及和负担得起的疗法的重大未满足需求的治疗解决方案，针对细胞衰老、与年龄相关的慢性炎症和组织退化等基本衰老机制。有关 Celularity 及其前沿再生医学解决方案的更多信息，请访问 www.celularity.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中的某些声明是 1995 年《私人证券诉讼改革法案》所定义的 “前瞻性声明”。这些前瞻性声明包括但不限于以下内容：(i) 我们未来的销售或销售增长；(ii) 交易的预期时间和完成情况；(iii) 我们对未来财务结果的预期，包括净销售额水平；(iv) 预计从交易中获得和使用的收益；(v) 我们对新产品的预期，包括我们的 510K 产品；(vi) Celularity 执行其战略优先事项的能力，包括推进其核心技术并使其运营和组织结构与这些优先事项保持一致；(vii) 我们产品的未来需求；以及 (viii) 融资交易的预期收益。除历史事实声明外，所有声明均为 “前瞻性声明”，包括与未来事件相关的声明。在某些情况下，您可以通过 “预期”、“相信”、“可以”、“可能”、“继续”、“期望”、“改善”、“可能”、“观察到”、“潜在”、“承诺”、“应该” 等术语（以及其他引用未来事件、条件或情况的词语或表达）来识别前瞻性声明。前瞻性声明基于 Celularity 当前的预期和假设。由于前瞻性声明涉及未来，因此它们受到固有的不确定性、风险和情况变化的影响，这些因素可能与前瞻性声明所考虑的情况有实质性差异，这些声明既不是历史事实的陈述，也不是未来表现的保证或承诺。许多因素可能导致实际结果与这些前瞻性声明中描述的结果有实质性差异，包括在 Celularity 截至 2024 年 12 月 31 日的年度报告中 “风险因素” 标题下列出的风险因素，该报告已于 2025 年 5 月 8 日和 2025 年 5 月 21 日分别提交给证券交易委员会（SEC），以及其他向 SEC 提交的文件。如果这些风险中的任何一个变为现实或基础假设被证明不正确，实际结果可能与这些前瞻性声明所暗示的结果有实质性差异。Celularity 可能还存在其他目前未知的风险，或 Celularity 目前认为不重要的风险，这些风险也可能导致实际结果与前瞻性声明中的结果不同。此外，这些前瞻性声明反映了 Celularity 截至本次沟通日期的当前预期、计划或未来事件的预测和观点。后续事件和发展可能导致评估发生变化。因此，不应将前瞻性声明视为 Celularity 在任何后续日期的观点，Celularity 不承担更新本声明中包含的前瞻性声明的义务，无论是由于任何新信息、未来事件、情况变化或其他原因，法律另有规定的除外。</p>
<p>投资者和媒体联系：</p>
<p>卡洛斯·拉米雷斯</p>
<p>Celularity Inc. 高级副总裁</p>
<p>carlos.ramirez@celularity.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05EYzBNaU0zTXpJNU5URTBJekl5TURVd01Eaz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05EYzBNaU0zTXpJNU5URTBJekl5TURVd01Eaz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDQxZDVhZDYtZTljMC00NzQ4LTg5NTYtZDMxMTgwNTM5NGIxLTEyMTY1NjItMjAyNS0xMi0xOC1lbg==/tiny/Celularity-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDQxZDVhZDYtZTljMC00NzQ4LTg5NTYtZDMxMTgwNTM5NGIxLTEyMTY1NjItMjAyNS0xMi0xOC1lbg==/tiny/Celularity-Inc-.png"/></p>

CELU

<p>Celularity Inc. 宣布了融资交易的具有约束力的条款清单，确保获得高达 1200 万美元的资金，以支持其在长寿和人类表现方面的战略优先事项。融资包括 700 万美元的高级担保定期贷款和 500 万美元的担保可转换票据，额外资金取决于某些条件。这些交易涉及 Philip A. Barach，属于免于注册要求的私募。此次融资旨在推动 Celularity 的胎盘衍生技术，并使其组织结构与战略目标保持一致</p>

<ul>
<li><strong>The contemplated financing transactions would provide up to $12 Million in capital to support Celularity’s strategic priorities around longevity and preservation of human performance.</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>拟议的融资交易将提供高达 1200 万美元的资金，以支持 Celularity 在延续生命和人类表现保护方面的战略优先事项。</strong></li>
</ul>
</div><p>FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced that it has entered into two binding term sheets for a senior secured term loan and a secured convertible note financing with Philip A. Barach, co-founder and former president of DoubleLine Capital LP, a Los Angeles-based investment management firm. The contemplated financing transactions are contingent upon the parties executing formal transaction agreements, which the parties expect to do shortly.</p>
<div class="lb-trans"><p>新泽西州弗洛汉公园，2025 年 12 月 18 日（全球新闻通讯）——Celularity Inc.（纳斯达克：CELU）（“Celularity”），一家应对与年龄相关和退行性疾病的再生和细胞医学公司，今天宣布已与 DoubleLine Capital LP 的联合创始人及前总裁 Philip A. Barach 签署了两份具有约束力的条款清单，涉及一项高级担保定期贷款和一项担保可转换票据融资。这些拟议的融资交易取决于各方签署正式交易协议，各方预计将很快完成此项工作。</p>
</div><p>Under the terms of the binding term sheets, Celularity expects to receive initial proceeds of $10.0 million, with the availability of additional funding of up to $2.0 million subject to certain conditions and the investor’s election, as will be set forth in the definitive agreements.</p>
<div class="lb-trans"><p>根据具有约束力的条款清单，Celularity 预计将获得 1000 万美元的初始收益，额外资金最多可达 200 万美元，具体取决于某些条件和投资者的选择，这将在最终协议中列明。</p>
</div><p>“This financing, when completed, is expected to provide flexibility to further evolve our mission, sharpening our focus on advancing our core placental-derived technologies and thoughtfully aligning our organizational structure and resources to support our strategic priorities around longevity and preservation of human performance,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer of Celularity. “We are grateful to Phil Barach’s commitment to partner with Celularity at an important moment in our progression. Phil’s investment reflects a deep appreciation for the scientific foundation of our platform and the long-term vision we are pursuing.”</p>
<div class="lb-trans"><p>“完成这项融资后，预计将为我们进一步发展使命提供灵活性，聚焦于推进我们的核心胎盘衍生技术，并合理调整我们的组织结构和资源，以支持我们在延续生命和人类表现保护方面的战略优先事项，” Celularity 的董事长兼首席执行官 Robert J. Hariri 博士表示。“我们感谢 Phil Barach 在我们发展重要时刻与 Celularity 合作的承诺。Phil 的投资反映了对我们平台科学基础的深刻理解和我们所追求的长期愿景。”</p>
</div><p>As contemplated in the binding term sheets, the senior secured term loan has a stated principal amount of $7.0 million and is secured by a first-priority lien on substantially all of Celularity’s assets, subject to certain customary exclusions and priority agreements. The secured convertible notes provide for aggregate commitments of up to $5.0 million, issuable in multiple tranches, and are convertible into shares of Celularity’s Class A common stock at a conversion price of $1.66 per share, subject to compliance with applicable Nasdaq Minimum Price rules and federal securities law requirements. In connection with the contemplated transactions, Celularity has agreed to issue warrants to purchase shares of its Class A common stock equal to 33% of the as-converted principal amount, representing additional consideration to the investor. The warrants will become exercisable six months following issuance, have an exercise price of $2.00 per share, and are subject to customary terms and conditions. The transactions will be conducted as private placements to an accredited investor.</p>
<div class="lb-trans"><p>根据具有约束力的条款清单，高级担保定期贷款的名义本金为 700 万美元，并以 Celularity 几乎所有资产的第一优先权利作为担保，受某些惯例排除和优先协议的限制。担保可转换票据提供高达 500 万美元的总承诺，可以分多个批次发行，并可按每股 1.66 美元的转换价格转换为 Celularity 的 A 类普通股，前提是符合适用的纳斯达克最低价格规则和联邦证券法要求。与拟议交易相关，Celularity 已同意发行购买其 A 类普通股的认股权证，数量相当于按转换后的本金金额的 33%，作为对投资者的额外对价。认股权证将在发行后六个月生效，行使价格为每股 2.00 美元，并受惯例条款和条件的限制。交易将作为对合格投资者的私募进行。</p>
</div><p>Philip A. Barach commented, “Dr. Hariri has built a company with pioneering science and a bold vision that, in my view, can be more fully realized going forward by better aligning its strategy, operations, and capital structure consistent with its mission to translate meaningful science into real-world impact. My decision to invest and to engage with the Company reflects a long-term commitment to providing financial support and constructive perspective as Celularity works through necessary changes and positions itself for a more disciplined and focused future.”</p>
<div class="lb-trans"><p>Philip A. Barach 评论道：“Hariri 博士建立了一家拥有开创性科学和大胆愿景的公司，我认为，通过更好地调整其战略、运营和资本结构，以符合其将有意义的科学转化为现实影响的使命，未来可以更充分地实现。我的投资决定和与公司的互动反映了对提供财务支持和建设性视角的长期承诺，因为 Celularity 在必要的变革中努力并为更有纪律和专注的未来做好准备。”</p>
</div><p>The securities described above are to be sold in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the ” Act”), and have not been registered under the Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. Pursuant to a registration rights agreement to be entered into with the investor, the Company has agreed to file one or more registration statements with the Securities and Exchange Commission (the “SEC”) covering the resale of the shares of Class A common stock underlying the convertible notes and warrants sold in the private placement.</p>
<div class="lb-trans"><p>上述证券将在免于 1933 年证券法（经修订）（“法案”）注册要求的私募中出售，且未在法案或适用的州证券法下注册。因此，除非根据有效的注册声明或适用的注册豁免，否则这些证券不得在美国提供或出售，并且不得在任何州或司法管辖区进行此类提供、招揽或销售，除非在该州或司法管辖区的证券法下进行注册或资格审查。根据与投资者签订的注册权利协议，公司已同意向证券交易委员会（“SEC”）提交一份或多份注册声明，涵盖在私募中出售的可转换票据和认股权证所对应的 A 类普通股的转售。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售或招揽购买本文所述证券的要约，也不构成在任何州或司法管辖区进行这些证券的销售，除非在该州或司法管辖区的证券法下进行注册或资格审查。</p>
</div><p><strong>About Celularity</strong></p>
<div class="lb-trans"><p><strong>关于 Celularity</strong></p>
</div><p>Celularity Inc. (Nasdaq: CELU) is a regenerative and aging-related cellular medicine company developing, manufacturing, and commercializing advanced biomaterial products and allogeneic and autologous cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies that target fundamental aging mechanisms like cellular senescence, age-related chronic inflammation, and tissue degeneration. For more information about Celularity and its cutting-edge regenerative medicine solutions, please visit www.celularity.com.</p>
<div class="lb-trans"><p>Celularity Inc.（纳斯达克：CELU）是一家再生和与衰老相关的细胞医学公司，开发、制造和商业化先进的生物材料产品以及源自产后胎盘的异体和自体细胞疗法。Celularity 相信，通过利用胎盘独特的生物学和现成的可用性，可以开发出解决全球有效、可及和负担得起的疗法的重大未满足需求的治疗解决方案，针对细胞衰老、与年龄相关的慢性炎症和组织退化等基本衰老机制。有关 Celularity 及其前沿再生医学解决方案的更多信息，请访问 www.celularity.com。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding: (i) our future sales or sales growth; (ii) the anticipated timing and completion of the transaction; (iii) our expectations for future financial results, including levels of net sales; (iv) the expected receipt and use of proceeds from the transactions; (v) our expectations regarding new products including our 510K products; (vi) Celularity’s ability to execute its strategic priorities, including advancing its core technologies and aligning its operations and organizational structure with those priorities; (vii) future demand for our products; and (viii) the anticipated benefits of the financing transactions. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “improving,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on May 8, 2025 and May 21, 2025, respectively, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p>
<div class="lb-trans"><p>本新闻稿中的某些声明是 1995 年《私人证券诉讼改革法案》所定义的 “前瞻性声明”。这些前瞻性声明包括但不限于以下内容：(i) 我们未来的销售或销售增长；(ii) 交易的预期时间和完成情况；(iii) 我们对未来财务结果的预期，包括净销售额水平；(iv) 预计从交易中获得和使用的收益；(v) 我们对新产品的预期，包括我们的 510K 产品；(vi) Celularity 执行其战略优先事项的能力，包括推进其核心技术并使其运营和组织结构与这些优先事项保持一致；(vii) 我们产品的未来需求；以及 (viii) 融资交易的预期收益。除历史事实声明外，所有声明均为 “前瞻性声明”，包括与未来事件相关的声明。在某些情况下，您可以通过 “预期”、“相信”、“可以”、“可能”、“继续”、“期望”、“改善”、“可能”、“观察到”、“潜在”、“承诺”、“应该” 等术语（以及其他引用未来事件、条件或情况的词语或表达）来识别前瞻性声明。前瞻性声明基于 Celularity 当前的预期和假设。由于前瞻性声明涉及未来，因此它们受到固有的不确定性、风险和情况变化的影响，这些因素可能与前瞻性声明所考虑的情况有实质性差异，这些声明既不是历史事实的陈述，也不是未来表现的保证或承诺。许多因素可能导致实际结果与这些前瞻性声明中描述的结果有实质性差异，包括在 Celularity 截至 2024 年 12 月 31 日的年度报告中 “风险因素” 标题下列出的风险因素，该报告已于 2025 年 5 月 8 日和 2025 年 5 月 21 日分别提交给证券交易委员会（SEC），以及其他向 SEC 提交的文件。如果这些风险中的任何一个变为现实或基础假设被证明不正确，实际结果可能与这些前瞻性声明所暗示的结果有实质性差异。Celularity 可能还存在其他目前未知的风险，或 Celularity 目前认为不重要的风险，这些风险也可能导致实际结果与前瞻性声明中的结果不同。此外，这些前瞻性声明反映了 Celularity 截至本次沟通日期的当前预期、计划或未来事件的预测和观点。后续事件和发展可能导致评估发生变化。因此，不应将前瞻性声明视为 Celularity 在任何后续日期的观点，Celularity 不承担更新本声明中包含的前瞻性声明的义务，无论是由于任何新信息、未来事件、情况变化或其他原因，法律另有规定的除外。</p>
</div><p>Investor and Media Contact:</p>
<div class="lb-trans"><p>投资者和媒体联系：</p>
</div><p>Carlos Ramirez</p>
<div class="lb-trans"><p>卡洛斯·拉米雷斯</p>
</div><p>Senior Vice President, Celularity Inc.</p>
<div class="lb-trans"><p>Celularity Inc. 高级副总裁</p>
</div><p>carlos.ramirez@celularity.com</p>
<div class="lb-trans"><p>carlos.ramirez@celularity.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05EYzBNaU0zTXpJNU5URTBJekl5TURVd01Eaz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwNDc0MiM3MzI5NTE0IzIyMDUwMDk="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NDQxZDVhZDYtZTljMC00NzQ4LTg5NTYtZDMxMTgwNTM5NGIxLTEyMTY1NjItMjAyNS0xMi0xOC1lbg==/tiny/Celularity-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NDQxZDVhZDYtZTljMC00NzQ4LTg5NTYtZDMxMTgwNTM5NGIxLTEyMTY1NjItMjAyNS0xMi0xOC1lbg==/tiny/Celularity-Inc-.png"/></p>

Celularity 达成融资交易的约束性条款以支持其战略愿景 | CELU 股票新闻